Eledon Pharmaceuticals/$ELDN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eledon Pharmaceuticals
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Ticker
$ELDN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
31
ISIN
US28617K1016
Website
ELDN Metrics
BasicAdvanced
$181M
-
-$0.32
-
-
Price and volume
Market cap
$181M
52-week high
$4.44
52-week low
$2.61
Average daily volume
177K
Financial strength
Current ratio
13.905
Quick ratio
13.596
Long term debt to equity
0.484
Total debt to equity
0.768
Management effectiveness
Return on assets (TTM)
-40.10%
Return on equity (TTM)
-38.15%
Valuation
Price to book
1.58
Price to tangible book (TTM)
2.2
Price to free cash flow (TTM)
-3.337
Growth
Earnings per share change (TTM)
-93.04%
3-year earnings per share growth (CAGR)
-49.44%
ELDN News
AllArticlesVideos
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
GlobeNewsWire·1 week ago
Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet
Seeking Alpha·3 weeks ago
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eledon Pharmaceuticals stock?
Eledon Pharmaceuticals (ELDN) has a market cap of $181M as of May 23, 2025.
What is the P/E ratio for Eledon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Eledon Pharmaceuticals (ELDN) stock is 0 as of May 23, 2025.
Does Eledon Pharmaceuticals stock pay dividends?
No, Eledon Pharmaceuticals (ELDN) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Eledon Pharmaceuticals dividend payment date?
Eledon Pharmaceuticals (ELDN) stock does not pay dividends to its shareholders.
What is the beta indicator for Eledon Pharmaceuticals?
Eledon Pharmaceuticals (ELDN) does not currently have a Beta indicator.